ACE2 decoy receptor with robust neutralization against Omicron subvariants shows therapeutic potential

Researchers in the United States have shown the inhalation of an angiotensin-converting enzyme 2 (ACE2) decoy receptor, sACE22.v2.4-IgG1, increases survival and ameliorates lung injury in K18-hACE2 transgenic mice infected with a lethal dose of the virulent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) gamma variant. Moreover, the engineered decoy binds tightly to spike (S) of BA.1 and BA.2 omicron, despite […]
Continue reading »